Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 1
2(40.0%)
5Total
N/A(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05180994Phase 1Recruiting

Topical Infliximab in Eyes With Penetrating Keratoplasty

Role: collaborator

NCT04232982Not ApplicableRecruiting

The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

Role: collaborator

NCT01950598Not ApplicableCompleted

Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers

Role: collaborator

NCT01819415Not ApplicableCompleted

Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD

Role: collaborator

NCT02126020Phase 1Withdrawn

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Role: collaborator

All 5 trials loaded